在神经退行性疾病中,高级甘化终端产品是神经退行性疾病
1Department of Biochemistry, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, 695 011, Kerala, India. cibin@sctimst.ac.in.
Journal of molecular neuroscience : MN
|December 9, 2024
概括
先进的糖化终产品 (AGEs) 通过促进蛋白质聚合和激活有害途径来驱动神经退行性疾病. 针对 AGE-RAGE 轴提供了一个有前途的治疗策略,用于阿尔茨海默氏症和帕金森病等疾病.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 先进的糖化终产品 (AGEs) 与神经退行性疾病的发病有关.
- AGEs有助于蛋白质交叉链接和聚合,这是这些疾病的关键特征.
- AGEs (RAGE) 轴的受体调解神经炎症,氧化应激和兴奋毒性,导致神经元死亡.
研究的目的:
- 探索针对AGE和RAGE轴在神经退行性疾病中的治疗潜力.
- 审查目前旨在减轻AGE-RAGE通路激活的治疗策略.
- 评估这些策略对阿尔茨海默病,帕金森病和亨廷顿病等疾病的前景.
主要方法:
- 关于AGE,RAGE和神经退行现有文献的综述.
- 对针对AGE产生和RAGE信号的治疗方法的分析.
- 检查 AGE-RAGE 相互作用在疾病进展中的作用.
主要成果:
- AGEs促进蛋白质聚合并激活RAGE,从而导致神经元损伤.
- 治疗策略的重点是减少AGE形成,阻断RAGE或抑制下游途径.
- 这些干预措施显示出减缓疾病进展的前景.
结论:
- AGE-RAGE轴是神经退行过程的重要贡献者.
- 针对这一轴代表了阿尔茨海默病,帕金森病和亨廷顿病的可行的治疗途径.
- 对AGE-RAGE调节的进一步研究可能会为目前难以治疗的神经系统疾病提供有效的治疗方法.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
01:15Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:22Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
01:05Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K